PlainRecalls
FDA Drug Low Class III Terminated

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.

Reported: March 8, 2023 Initiated: February 17, 2023 #D-0354-2023

Product Description

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.

Reason for Recall

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Details

Units Affected
4,392 bottles
Distribution
Nationwide in the USA and Puerto Rico
Location
Hauppauge, NY

Frequently Asked Questions

What product was recalled?
Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.. Recalled by Sciegen Pharmaceuticals Inc. Units affected: 4,392 bottles.
Why was this product recalled?
Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 8, 2023. Severity: Low. Recall number: D-0354-2023.